Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Bone as an endocrine regulator of lipid and energy metabolism

Liu H., Zhao J., Liu L., Ying W., Liu S., Luo E.

Narrative Review on Systemic / IV, published in Rev Endocr Metab Disord (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Rev Endocr Metab Disord (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42154165
PMCID
PMC13188346
DOI
10.1007/s11154-026-10052-7

Abstract (original English)

Bone has long been viewed as a structural organ with essential roles in mechanical support and mineral homeostasis. However, accumulating evidence shows that the skeleton is also an active endocrine organ that contributes to the regulation of systemic energy metabolism. Bone remodeling requires substantial energy, and skeletal cells, including osteoblasts, osteocytes, and bone marrow adipocytes, secrete endocrine factors that influence adipose tissue plasticity, glucose homeostasis, insulin sensitivity, and energy expenditure. In this Review, we summarize current knowledge of bone-derived endocrine factors, or osteokines, and their roles in lipid and energy metabolism. We discuss how signals from osteoblasts, osteocytes, and marrow adipose tissue link skeletal state to peripheral metabolic adaptation. We highlight key osteokines, including osteocalcin, adiponectin, sclerostin, FGF23, PTHrP, lipocalin-2, and components of the RANKL-OPG axis, and summarize evidence for their systemic metabolic effects. Collectively, these findings identify bone as an active regulator of whole-body energy homeostasis rather than a passive target of metabolic signals. Understanding how skeletal endocrine programs interact with adipose tissue and other metabolic organs may offer new ideas and therapeutic opportunities for metabolic diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research